Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biogen, Inc. (NQ: BIIB)
235.72 USD  +4.04 (+1.74%)
Official Closing Price  /  Updated: 6:08 PM EDT, Aug 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,021,700
Open 233.37
Bid (Size) 235.50 (80)
Ask (Size) 238.00 (1)
Prev. Close 231.68
Today's Range 233.18 - 236.64
52wk Range 216.12 - 358.41
Shares Outstanding 211,007,945
Dividend Yield N/A
Performance
YTD
-22.64%
-22.64%
1 Month
+1.39%
+1.39%
3 Month
+2.30%
+2.30%
6 Month
-29.21%
-29.21%
1 Year
-31.50%
-31.50%
Top News
More News
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate,... Read More
from GlobeNewswire News Releases
Notable Friday Option Activity: BIIB, BMRN, EL
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (BIIB), where a total of 6,128 contracts have traded so far, representing... Read More
category Stocks
from Market News Video
More News
Read More
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
from PR Newswire
Why The 2 Biggest Biotech Stocks Were Just Hit With Downgrades
from Investor's Business Daily
UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues
category companyNews
from Reuters: Company News
Biogen Inc Down 26.9% Since SmarTrend Downtrend Call (BIIB)
from Comtex SmarTrend® News Briefs
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
category Market News , AKCA , GSK , and 3 more.
from Motley Fool
UPDATE 3-U.S. FDA says some data testing Novartis' $2 mln gene therapy was manipulated
category companyNews
from Reuters: Company News
UPDATE 2-FDA says some data testing Novartis' $2 mln gene therapy was manipulated
category companyNews
from Reuters: Company News
Peek Under The Hood: SPXE Has 13% Upside
category ETFs
from ETF Channel
5 Reasons Novartis Shareholders Aren't Shaken
category Market News , NVS , REGN , and 1 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.